Gyre Therapeutics, Inc.
GYRE
$8.68
-$2.53-22.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2,825.25% | -108.81% | -68.14% | -53.16% | 107.46% |
| Total Depreciation and Amortization | 13.59% | 3.74% | 90.76% | -42.65% | 34.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 230.51% | -62.87% | 77.57% | -47.58% | -97.88% |
| Change in Net Operating Assets | -47.47% | -124.81% | 83.52% | -46.17% | -165.67% |
| Cash from Operations | 95.32% | -259.79% | 131.42% | -290.46% | -14.17% |
| Capital Expenditure | -287.69% | 109.38% | 52.40% | -530.30% | 90.06% |
| Sale of Property, Plant, and Equipment | -99.28% | 2,860.00% | -102.29% | 336.00% | -70.06% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 194.61% | -30.67% | 75.99% | 0.06% | -402.43% |
| Cash from Investing | 198.15% | 16.05% | 71.15% | -14.58% | -639.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.07% | 255.88% | 36.00% | -58.21% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 67.03% | -634.00% | 57.98% | -- | -- |
| Cash from Financing | 39.42% | 197.53% | 107.69% | -76.29% | -73.68% |
| Foreign Exchange rate Adjustments | 119.61% | -340.57% | 235.90% | -69.57% | -119.91% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 179.74% | -1,654.55% | 98.31% | -267.56% | -150.12% |